Respirerx Pharmaceuticals Inc.’s lead GABA-A receptor potentiator, KRM-II-81, has advanced to the next level of evaluation within the National...

Alzecure Pharma AB has selected a TrkA negative allosteric modulator drug candidate, ACD-137, to advance into the preclinical development phase.

Guangzhou Fermion Technology Co. Ltd. has announced IND clearance by China’s National Medical Products Administration (NMPA) for FZ-008-145 to treat pain.

Novel non-addicting analgetic therapies are urgently needed to reduce the use of opiates as painkillers. With the recent discovery that nicotinic acetylcholine receptors (nAChRs) in the immune system can be stimulated to decrease the release of pro-inflammatory cytokines, the cholinergic anti-inflammatory systems (CAS) have generated significant interest in treating pain associated with inflammation.

Just over a year since the last anti-nerve growth factor (NGF) antibody program was axed, the target is poised for a revival, with Levicept Ltd. announcing it has completed recruitment to a phase II trial of LEVI-04 in the control of chronic pain caused by osteoarthritis.